Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

Introduction Most patients with pancreatic cancer present with advanced stage, incurable
disease. However, patients with high-grade precancerous lesions and many patients with …

Cancer has been constantly evolving and so is the research pertaining to cancer diagnosis
and therapeutic regimens. Early detection and specific therapeutics are the key features of …

Core fucosylation of N-linked glycoproteins has been linked to the functions of glycoproteins
in physiological and pathological processes. However, quantitative characterization of core …

Hypoxia-inducible factors (HIFs) and NF-κB play essential roles in cancer cell growth and
metastasis by promoting angiogenesis. Heat shock protein 90 (Hsp90) serves as a regulator …

The delayed diagnosis of pancreatic cancer has resulted in rising mortality rate and low
survival rate that can be circumvented using potent theranostics biomarkers. The treatment …

Gene expression microarrays have identified many tumor markers and therapeutic targets
for pancreatic ductal adenocarcinoma (PDAC). However, microarray profilings have limited …

The availability of robust classification algorithms for the identification of high risk individuals
with resectable disease is critical to improving early detection strategies and ultimately …

Pancreatic cancer (PC) is an aggressive disease with high mortality rates, however, there is
no blood test for early detection and diagnosis of this disease. Several research groups …

Goals of investigation: The 5-year survival rate for pancreatic ductal adenocarcinoma
(PDAC) has remained at< 5% for decades because no effective therapies have been …